{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-014987","form_type":"8-K","ticker":"STTK","cik":"0001680367","company_name":"Shattuck Labs, Inc.","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.874353+00:00","generated_at":"2026-05-15T19:42:30.230057+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Shattuck Labs reports FY2025 net loss $48.8M; SL-325 Ph1 data expected Q2 2026","bullets":["Net loss for FY2025 was $48.8M ($0.70/diluted share), vs $75.4M ($1.49) in FY2024.","Cash and investments at Dec 31, 2025 were $78.1M; after $21.4M ATM raise in Q1 2026, pro forma cash ~$94.5M.","SL-325 Phase 1 in healthy volunteers nearly complete; data expected Q2 2026, Phase 2 in Crohn's planned Q3 2026.","R&D expenses fell to $35.3M from $67.2M, driven by discontinuation of SL-172154 program.","Michael Choi, M.D., appointed VP of Clinical Development; cash runway guidance extended into 2029."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-014987","json":"https://secwatch.observer/filing/0001628280-26-014987.json","markdown":"https://secwatch.observer/filing/0001628280-26-014987.md","text":"https://secwatch.observer/filing/0001628280-26-014987.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680367/000162828026014987/0001628280-26-014987-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680367/000162828026014987/sttk-20260305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:42:30.230057+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}